daawaynta kansarka sanbabada hiddo-wade

Fahamka doorka daawaynta kansarka sanbabada hiddo-wade ayaa muhiim u ah maaraynta kansarka sanbabada ee gaarka ah oo waxtar leh. Maqaalkani waxa uu sahaminayaa sida baaritaanka hidde-sidaha uu u sheego go'aamada daaweynta, noocyada isbeddellada sida caadiga ah laga helo kansarka sanbabada, iyo daawaynta lagu bartilmaameedsado isbeddelladan gaarka ah daawaynta kansarka sanbabada hiddo-wade. Isbeddelladani waxay ku dhici karaan hidde-sideyaasha xakameynaya koritaanka unugyada, qaybinta, iyo hagaajinta. Aqoonsiga isbeddelladan waa lama huraan sababtoo ah waxay hagi kartaa xeeladaha daaweynta waxayna hagaajin kartaa natiijooyinka bukaanka. Machadka Cilmi-baarista Kansarka ee Shandong Baofa, waxaan mudnaanta siinaa fahamka muuqaalka hidda-socodka ee kansarka sanbabada bukaan kasta. Waa maxay Isbeddellada Hidde-raaca?Daaweynta kansarka sanbabada hidde-is-beddelka waa isbeddel ku yimaada taxanaha DNA-da oo keeni kara hab-dhaqan unug aan caadi ahayn. Isbeddelladan waa la dhaxli karaa ama la heli karaa inta uu qofku nool yahay. Kansarka sambabada, isbeddellada la helay ayaa aad ugu badan waxaana inta badan sababa arrimo deegaan sida sigaar cabista ama soo-gaadhista wasakhowga. Isbeddelladani waxay carqaladayn karaan hababka caadiga ah ee unugyada, taasoo keenta korriin aan la xakameynin iyo samaynta burooyin. Fahamka isbeddelladan ayaa muhiim u ah doorashada habka daaweynta saxda ah. Waa kuwan qaar ka mid ah kuwa ugu caansan:EGFR (Qaybiyaha Cunsurka Kobaca Epidermal): Isbeddellada EGFR waxay ku badan yihiin kansarka sambabada unugyada aan yareyn (NSCLC), gaar ahaan adenocarcinomas. Isbeddelladani waxay unugyada kansarka ka dhigi karaan kuwo xasaasi u ah daawaynta la beegsanayo qaarkood.ALK (anaplastic Lymphoma Kinase): Dib-u-habaynta ALK waa isbeddellada kale ee la beegsan karo ee laga helo NSCLC. Kahortagayaasha ALK waxay muujiyeen guulo la taaban karo oo ku saabsan daawaynta burooyinka isbeddelkan.ROS1: Si la mid ah ALK, isku-dhafka ROS1 ayaa kicin kara korriinka kansarka sanbabada. ROS1 inhibitors ayaa diyaar u ah bukaanada qaba ROS1-positive NSCLC.BRAF: Isbeddellada BRAF, gaar ahaan beddelka V600E, waxaa laga heli karaa NSCLC. BRAF inhibitors waxaa loo isticmaali karaa in lagu beegsado isbedelladan.KRAS: Isbeddellada KRAS waxay ku badan yihiin adenocarcinoma sambabada. Iyadoo taariikh ahaan ay adag tahay in la beegsado, daawayn cusub ayaa soo baxaya si loo daweeyo kansarka sambabada ee KRAS-is-beddelay.PD-L1 (Barnaamijka Dhimashada-Ligand 1): In kasta oo aysan ahayn beddelaad hidde-siyeedka dareenka dhaqameed, muujinta PD-L1 waa biomarker saadaalin kara jawaabta tallaalka. Muujinta sare ee PD-L1 waxay muujin kartaa in bukaanku u badan yahay inuu ka faa'iidaysto immunotherapy.Daaweynta kansarka sanbabada hidde-is-beddelka waxaa lagu gartaa iyada oo loo marayo baaris dhammaystiran oo hidde-side ah, oo sidoo kale loo yaqaan baaritaanka biomarker ama astaanta unugyada. Baaritaankaani wuxuu falanqeynayaa unugyada burooyinka ama, xaaladaha qaarkood, shaybaarka dhiigga si loo ogaado isbeddellada hidde-sidaha gaarka ah ee horseeda koritaanka kansarka. Natiijooyinka baaritaanadan waxay ka caawiyaan dhakhaatiirta kansarka inay shakhsiyeeyaan qorshayaasha daawaynta si ay u beegsadaan sifooyinka gaarka ah ee kansarka bukaan kasta. Machadka Cilmi-baarista Kansarka ee Baofa wuxuu adeegsadaa tignoolajiyada casriga ah ee baaritaanka hidda-socodkaTaxanaha Jiilka Xiga (NGS): NGS waa hab tijaabo ah oo dhammaystiran oo isku mar wada falanqayn kara hiddo-wadeyaal badan. Tani waxay u oggolaaneysaa in la ogaado isbeddello badan oo kala duwan iyo isbeddellada kale ee genomic.Falcelinta Silsiladda Polymerase (PCR): PCR waa hab tijaabo ah oo diiradda saaraya kaas oo loo isticmaalo in lagu ogaado isbeddellada gaarka ah ama dib-u-habaynta hiddo-wadaha.Fluorescence In Situ Hybridization (FISH): KALUUNKA waxa loo isticmaalaa in lagu ogaado dib u habaynta hidda-sidaha, sida isku-dhafka ALK iyo ROS1.Immunohistochemistry (IHC): IHC waxa loo isticmaalaa in lagu ogaado muujinta borotiinka, sida PD-L1, kaas oo kaa caawin kara saadaalinta jawaabta difaaca jirka Tijaabada waa in sida ugu dhaqsaha badan loo sameeyaa habka qorshaynta daawaynta si daawaynta la beegsanayo loo tixgeliyo bilowga hore. Waxa kale oo muhiim ah in dib loo tijaabiyo haddii kansarku sii socdo ama haddii doorashooyin cusub oo daawaynta la heli karo daawaynta kansarka sanbabada hiddo-wade. Daawayntan waxaa loogu talagalay inay farageliyaan koritaanka, kala qaybinta, iyo faafitaanka unugyada kansarka iyadoo la yareynayo dhaawaca unugyada caadiga ah. Habka daawaynta ee cisbitaalka Baofa ee shakhsi ahaaneed ayaa adeegsada daawaynta la beegsanayo ee ugu horumarsan. Daawooyinkani waxay xannibaan dhaqdhaqaaqa borotiinka EGFR, kaas oo inta badan aad u firfircoon unugyada kansarka ee leh isbeddelladan. Kahortayaasha caadiga ah ee EGFR waxaa ka mid ah:Gefitinib (Iressa)Erlotinib (Tarceva)Afatirib (Gilotrif)Osimertinib (Tagrisso): Badanaa daawaynta safka kowaad ee EGFR-mutated NSCLC.ALK InhibitorsALK inhibitors waxaa loo isticmaalaa in lagu daweeyo kansarka sanbabada iyadoo la isticmaalayo dib u habeynta ALK. Daawooyinkani waxay xannibaan dhaqdhaqaaqa borotiinka ALK, kaas oo inta badan si aan caadi ahayn ugu firfircoon unugyada kansarka leh dib-u-habayntan. Kahortagayaasha caadiga ah ee ALK waxaa ka mid ah:Crizotinib (Xalkori)Alectinib (Alecensa)Ceritinib (Zykadia)Brigatinib (Aunbrig)Lorlatinib (Lorbrena)ROS1 InhibitorsROS1 inhibitors waxaa loo isticmaalaa in lagu daaweeyo kansarka sanbabada oo leh ROS1 fusions. Daawooyinkani waxay xannibaan dhaqdhaqaaqa borotiinka ROS1, kaas oo inta badan si aan caadi ahayn ugu firfircoon unugyada kansarka leh isku-dhafkan. ROS1 horjoogayaasha caadiga ah waxaa ka mid ah:Crizotinib (Xalkori)Entrectinib (Rozlytrek)BRAF Inhibitors BRAF inhibitors waxaa loo isticmaalaa in lagu daweeyo kansarka sanbabada leh isbeddellada BRAF, gaar ahaan isbeddelka V600E. Daawooyinkani waxay xannibaan dhaqdhaqaaqa borotiinka BRAF, kaas oo inta badan si xad dhaaf ah u firfircoon unugyada kansarka leh isbeddelladan. Kahortayaasha BRAF ee caadiga ah waxaa ka mid ah:Dabrafenib (Tafinlar)Trametinib (Mekinist): Inta badan waxaa loo isticmaalaa in lagu daro dabrafenib.KRAS G12C InhibitorsSotorasib (Lumakras) iyo Adagrasib (Krazati) waa tusaalayaal KRAS G12C inhibitors ee loo isticmaalo in lagu daweeyo kansarka sanbabada leh isbeddelka KRAS ee gaarka ah. Waxay u shaqeeyaan iyaga oo xannibaya dhaqdhaqaaqa borotiinka KRAS ee is-beddelay.Immunotherapy iyo Genetic MutationsImmunotherapy waa nooc ka mid ah daaweynta kansarka kaas oo ka caawiya habka difaaca jidhku inuu la dagaallamo kansarka. Halka immunotherapy aan si toos ah loo beegsanayn daawaynta kansarka sanbabada hiddo-wade, isbeddellada hidde-sideyaasha qaarkood iyo biomarkers, sida muujinta PD-L1 iyo culeyska mutational mutational (TMB), waxay saadaalin karaan jawaabta tallaalka. Bukaanka leh muujinta sare ee PD-L1 ama TMB sare waxay u badan tahay inay ka faa'iidaystaan ​​​​immunotherapy. Machadka Cilmi-baarista Kansarka ee Shandong Baofa, waxaanu ku darsanaa daaweynta difaaca jirka iyo hababka kale ee daawaynta ee hab dhamaystiran. Daawaynta cusub ee la beegsaday iyo daawaynta difaaca jirka ayaa la soo saaray oo lagu tijaabiyay tijaabooyin caafimaad. Cilmi-baarayaashu waxay sidoo kale ka shaqeynayaan inay aqoonsadaan kuwa cusub daawaynta kansarka sanbabada hiddo-wade taas oo lagu beegsan karo daawaynta cusub. Marka fahamkayaga ku saabsan hidde-sideyaasha kansarka sanbabada uu soo hagaagayo, waxaan filan karnaa inaan aragno xitaa xulashooyinka daawaynta ee gaarka loo leeyahay oo waxtarka leh ee bukaanka. Machadka Cilmi-baarista Kansarka ee Shandong Baofa waxaa ka go'an inuu ku sii jiro safka hore ee horumarkan. Shaxda Sawirka: Daawaynta La Beegsado ee ku Salaysan Isbeddelka Daawaynta La BartilmaameedsadaySharaxaaddaEGFROsimertinib, Gefitinib, Erlotinib, Afatiniblock EGFR borotiinka dhaqdhaqaaqa ALKAlectinib, Crizotinib, borotiinka ALKeritiniblock, Hawlaha daawaynta kansarka sanbabada hiddo-wade waxay lagama maarmaan u tahay hagaajinta natiijooyinka bukaanka qaba kansarka sanbabada. Tijaabada hidde-sidaha ayaa kaa caawin karta in la ogaado isbeddellada gaarka ah ee lagu beegsan karo daawaynta shakhsi ahaaneed. Maaddaama fahamkayaga ku saabsan hidde-sideyaasha kansarka sanbabada uu sii korayo, waxaan filan karnaa inaan aragno xitaa daaweyn waxtar leh oo la beegsanayo cudurkan ba'an. Booqo Shandong Baofa Machadka Cilmi-baarista Kansarka si aan wax badan uga ogaano habkayaga dhamaystiran ee daryeelka kansarka sanbabada.Afeef: Macluumaadkan waxaa loogu talagalay ujeeddooyin waxbarasho oo keliya mana aha in loo tixgeliyo talo caafimaad. Had iyo jeer la tasho xirfadle daryeel caafimaad oo aqoon u leh ogaanshaha iyo daaweynta xaaladaha caafimaadka.Tixraacyada Machadka Kansarka Qaranka. www.cancer.govAmerican Cancer Society. www.cancer.org